Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.

Related LLY
Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
Here's How Lilly And Merck Are Faring In The Cancer Drug Wars: Earnings Out Next Week (Seeking Alpha)

In a report published Friday, Goldman Sachs Group reiterated its Sell rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $39.00 to $42.00.

Goldman Sachs noted, “We reiterate our Sell rating on LLY shares (relative to our Attractive coverage view on Pharma) and would take profits on recent strength driven by what we believe is a solanezumab hope-induced trade, which we see as premature. Based on our analysis, LLY shares already reflect $7 bn in Sola optionality value and a 50% probability of sola success, driven by the hint of efficacy seen in a pooled analysis of both studies in secondary endpoints. Data at ANA on Oct 8 will be a key to either supporting or significantly challenging that view. We are skeptical about a meaningful benefit and at the very best, expect that LLY will have to run another confirmatory Phase 3 clinical trial for 18 months in mild patients if the efficacy signal is based on a meaningful clinical benefit. This pushes the timeline out by 3-4 years.”

Eli Lilly & Co. closed on Thursday at $47.15.

Latest Ratings for LLY

Sep 2016Goldman SachsUpgradesNeutralBuy
Sep 2016JP MorganMaintainsOverweight
Sep 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!